Table 1.
Patients characteristics.
| Variable | Study group (n = 82) | Cytology + (n = 6) | OSNA + (n = 25) | Cytology + /OSNA + (n = 4) |
|---|---|---|---|---|
| Sex | ||||
| Men | 44 (53.7%) | 3 (50%) | 15 (60%) | 2 (50%) |
| Women | 38 (46.3%) | 3 (50%) | 10 (40%) | 2 (50%) |
| Age | ||||
| Median (range) | 65 (40–84) | |||
| < 65 years | 41 (50%) | 3 (50%) | 13 (52%) | 2 (50%) |
| ≥ 65 years | 41 (50%) | 3 (50%) | 12 (48%) | 2 (50%) |
| Lauren’s type | ||||
| Intestinal | 35 (42.7%) | 1 (16.7%) | 9 (36%) | 1 25%) |
| Mixed | 16 (19.5%) | 2 (33.3%) | 6 (24%) | 1 (25%) |
| Diffuse | 22 (26.8%) | 2 (33.3%) | 8 (32%) | 1 (25%) |
| Unknown | 9 (11.0%) | 1 (16.7%) | 2 (8%) | 1 (25%) |
| (y)pT | ||||
| 0 | 8 (9.8%) | – | – | – |
| 1 | 12 (14.6%) | – | 3 (12%) | – |
| 2 | 11 (13.4%) | – | 3 (12%) | – |
| 3 | 29 (35.4%) | 1 (16.7%) | 12 (484%) | 1 (25%) |
| 4a | 15 (18.3%) | 3 (50%) | 2 (8%) | – |
| 4b | 7 (8.5%) | 2 (33.3%) | 5 (20%) | 3 (75%) |
| (y)pN | ||||
| 0 | 37 (45.1%) | – | 10 (40%) | – |
| 1 | 13 (15.9%) | – | 2 (8%) | – |
| 2 | 12 (14.6%) | 1 (16.7%) | 3 (12%) | 1 (25%) |
| 3a | 15 (18.3%) | 3 (50%) | 7 (28%) | 2 (50%) |
| 3b | 5 (6.1%) | 2 (33.3%) | 3 (12%) | 1 (25%) |
| (y)pM | ||||
| 0 | 71 (86.6%) | – | 17 (68%) | – |
| 1 | 11 (13.4%) | 6 (100%) | 8 (32%) | 4 (100%) |
| (y)pTNM stage | ||||
| 0 | 8 (9.8%) | – | – | – |
| IA | 12 (14.6%) | – | 3 (12%) | – |
| IB | 6 (7.3%) | – | 2 (8%) | – |
| IIA | 10 (12.2%) | – | 5 (20%) | – |
| IIB | 12 (14.6%) | – | 1 (4%) | – |
| IIIA | 6 (7.3%) | – | 2 (8%) | – |
| IIIB | 11 (13.4%) | – | 2 (8%) | – |
| IIIC | 6 (7.3%) | – | 1 (4%) | – |
| IV | 11 (13.4%) | 6 (100%) | 9 (36%) | 4 (100%) |
| Neoadjuvant chemotherapy | ||||
| Yes | 62 (75.6%) | 3 (50%) | 20 (80%) | 3 (75%) |
| No | 20 (24.4%) | 3 (50%) | 5 (20%) | 1 (25%) |
| No. of neoadjuvant chemotherapy cycles | ||||
| Median (range) | 4 (1–8) | N/a | N/a | N/a |
| Tumour regression grade | ||||
| 1 | 6 (9.8%) | – | – | – |
| 2 | 15 (24.6%) | – | 6 (%) | – |
| 3 | 25 (41%) | 2 (66.7%) | 7 (28%) | 2 (%) |
| 4 | 15 (24.6%) | 1 (33.3%) | 6 (40%) | 1 (%) |
| Type of gastrectomy | ||||
| Proximal | 14 (17.1%) | 1 (7.1%) | 3 (31.6%) | 1 (25%) |
| Distal | 36 (43.9%) | – | 10 (36.8%) | – |
| Total | 32 (39%) | 5 (15.6%) | 12 (31.6%) | 3 (75%) |
| Cytology | ||||
| Positive | 6 (7.3%) | N/a | 4 (16%) | N/a |
| Negative | 76 (92.7%) | 21 (84%) | ||
| OSNA assay | ||||
| Positive | 25 (30.5%) | 4 (66.7%) | N/a | N/a |
| Negative | 57 (69.5%) | 2 (33.3%) | ||
N/a not applicable, (y)pT (post neoadjuvant) pathological primary tumour stage, (y)pN (post neoadjuvant) pathological nodal stage, (y)pM (post neoadjuvant) pathological distant metastasis stage, (y)pTNM (post neoadjuvant) pathological tumour, node, metastasis, OSNA One-Step Nucleic Acid Amplification Assay.